The Quantellect read.As of Nov 19, 2026, 5 active firms cover Context Therapeutics Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $4.00 to $9.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $6.40 sits 3838% above the current $0.16. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.42 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.40
+3838.5% upside
Average target across 5 active firms as of Nov 19, 2026 vs $0.16 current
Highest Target$9.00
Average Target$6.40
Lowest Target$4.00
Detailed analyst forecasts for CNTX
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate CNTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CNTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.11 – $-0.07 · 5 analysts · -40% YoY
Next period, 5 analysts expect Context Therapeutics Inc to earn $-0.08 a share (range $-0.11 – $-0.07), versus $-0.14 a year earlier. Full-year consensus is $-0.41, growing to $-0.42 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Context Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CNTX.
#1
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$4.00+2361.5% to target
Overall win rate
51%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton CNTX
Overall win rate
38%
+ Follow
#3
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$5.00+2976.9% to target
Overall win rate
24%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$9.00+5438.5% to target
Overall win rate
22%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #567
Buy
$4.00+2361.5% to target
Overall win rate
30%
+ Follow
CNTX stock forecast FAQ
What is CNTX's average 12-month price target?+
The 5 active firms with a live target average $6.40 for Context Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $4.00 low, as of Nov 19, 2026.
Is CNTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CNTX?+
The Street-high target is $9.00 (D. Boral Capital), and the Street-low is $4.00 (Maxim Group). The average of all 5 active-firm targets is $6.40.
How many active Wall Street firms cover CNTX?+
5 active firms have a recognized rating on Context Therapeutics Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CNTX?+
Among analysts who currently cover CNTX, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $4.00 target.
What is Context Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.11 – $-0.07) across 5 analysts. Full-year EPS is projected at $-0.41, rising to $-0.42 the following year.
How much revenue is Context Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CNTX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate CNTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CNTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.